ValoreQ4, 24TTMSpese di vendita, generali e amministrative——Ricerca e sviluppo——Reddito operativo——Proventi non operativi, Totale——Oneri finanziari, al netto degli interessi capitalizzati——Proventi non operativi, esclusi gli oneri finanziari——Entrate/uscite straordinarie——Utile al lordo delle imposte——Quota di utile——Imposte——Interessi di minoranza——Altri proventi/oneri al netto delle imposte——Utile netto al lordo delle attività cessate——Attività cessate——Utile netto——Regolazione della diluizione——Dividendi privilegiati——Utile netto diluito attribuibile agli azionisti ordinari——Utile base per azione (EPS base)——Utile diluito per azione (EPS diluito)——Numero medio di azioni ordinarie in circolazione——Azioni diluite in circolazione——EBITDA——EBIT——Costo del fatturato——Altri costi del venduto——Ammortamento e svalutazione (liquidità)——
Cybin Inc
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025.